Target Audience

This activity is specifically designed for:

  • Policy makers

Learning Objectives

At the end of the course, learners should be able to:

  • Describe the value of diagnostics in clinical decision making and disease control for COVID-19 and other diagnostics for diseases of public health importance

  • Accelerate policy development by collaborating with different stakeholders to assess acceptable risks as a trade-off for incremental patient or societal benefits in the use of diagnostic tests

  • Participate in a community of practice to share best practices and updates on evidence to inform policy


Testing strategies and policy development have become increasingly complex and for the COVID-19 pandemic, there is limited time to conduct research to inform policy. Addressing these issues, the agenda is as follows:

  • Measurements of diagnostic test performance and use of predictive values

  • Difference between evaluation, validation and verification

  • Key considerations in policy development for diagnostic tests for COVID-19 and other infectious diseases

Course Directors

Professor Rosanna Peeling, London School of Hygiene & Tropical Medicine, UK

Professor David Heymann, London School of Hygiene & Tropical Medicine, UK


  • Dr. Noah Fongwen, London School of Hygiene and Tropical Medicine & Africa CDC, UK

  • Scott Chiossi, Chatham House, UK

  • Carlos Gouvea, Latin American Alliance for In Vitro Diagnostic Development (ALADDiV), Brazil

  • Dr. Sidney Yee, DxD Hub, Association of Southeast Asian Nations (ASEAN), Singapore

  • Dr. Jaime Montoya, Council for Health Research and Development, Association of Southeast Asian Nations (ASEAN), Philippines

Learn more!

Add your email to the mailing list to get the latest updates.